Speech-Language Pathologists in Corry, PA Accepting Medicare
4 Speech-Language Pathologists found. Showing 1 - 4
 Ms. Susan Eileen Wisniewski, MS CCC-SLP/L Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 640 Worth St, Corry, PA 16407 Phone: 814-664-9606 Fax: 814-665-0036 |
Mrs. Brenda L Gastecki, MA, CCC-SLP/L Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 11050 W Pleasant St, Corry, PA 16407 Phone: 814-664-2622 Fax: 814-664-2622 |
Amber Lynn Trask, M.A.,CCC-SLP/L Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 11347 W Pleasant St, Corry, PA 16407 Phone: 814-823-7006 |
Kelsey Jayne Beichner, M.S. SLP-CF Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 640 Worth St, Corry, PA 16407 Phone: 814-664-9606 Fax: 814-665-0036 |
News Archive
Researchers develop new strategy to control inflammation without serious side effects
A potential new strategy to developing new drugs to control inflammation without serious side effects has been found by Georgia State University researchers and international colleagues.
Rowan University partners with DMHAS to provide treatment services for people with substance abuse disorders
The Department of Family Medicine at the Rowan University School of Osteopathic Medicine has entered into a two-year $973,000 agreement with the New Jersey Department of Human Services Division of Mental Health Addiction Services to provide early intervention and treatment services for individuals who have, or are at risk for, substance abuse disorders.
Human-gut-on-a-chip model offers hope for patients suffering from IBD
It's estimated that as many as 1,000,000 Americans suffer from inflammatory bowel diseases (IBD), such as ulcerative colitis and Crohn's disease, which cause mild to severe symptoms that at best can be managed and at worst can lead to life-threatening complications.
GeparQuinto study data on bevacizumab plus chemotherapy in early breast cancer to be presented at 33rd CTRC-AACR
Results of the GeparQuinto study, randomized Phase III efficacy data on the use of bevacizumab plus chemotherapy to treat women with early breast cancer will be presented at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium.
› Verified 9 days ago
Chiropractors
Optometrists
Physical Therapists
Speech-Language Pathologists
Occupational Therapists
Podiatrists